<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647619</url>
  </required_header>
  <id_info>
    <org_study_id>2639063</org_study_id>
    <secondary_id>2013-001221-13</secondary_id>
    <nct_id>NCT02647619</nct_id>
  </id_info>
  <brief_title>Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF</brief_title>
  <official_title>A Randomized Controlled Trial (RCT) Comparing Clostridium Histolyticum With Needle Aponeurotomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim:&#xD;
&#xD;
      Clinical RCT comparing functional results and recurrence rate following enzymatic treatment&#xD;
      vs. needle aponeurotomy.&#xD;
&#xD;
      Materials and methods:&#xD;
&#xD;
      30° or more contracture of only one metacarpophalangeal (MCP) joint contracture of one of the&#xD;
      three ulnar digits and less than 20° for the adjacent proximal interphalangeal (PIP) joint.&#xD;
      Patients with primary disease of the hand. Total of 80 patients needed to detect difference&#xD;
      of 13.5°.&#xD;
&#xD;
      1) Needle aponeurotomy 2) Clostridium Histolyticum treatment. Clinical follow ups 1,4 weeks,&#xD;
      16 weeks and 1,2 and 5 years. Functional outcome scores: URAM, Quick Dash, EQ5D, brief MHQ,&#xD;
      VAS pain and VAS patient satisfaction. Total passive extension contracture reduction,&#xD;
      recurrence rate and registration of complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open surgery (fascieectomy) has traditionally been considered the gold standard of treatment&#xD;
      for Dupytren´s disease (Dd) despite considerable risk of complications.&#xD;
&#xD;
      There is an increasing interest in Scandinavia in the treatment of Dd with Clostridium&#xD;
      Histolyticum (Xiapex ®, Auxillium). However the enzyme is expensive and long-term effects are&#xD;
      not well documented. More studies are needed to analyze both short and long term clinical&#xD;
      outcome as well as cost-benefit analysis.&#xD;
&#xD;
      The treatment arm of Xiapex in this study follows the recommendation as by the producer.&#xD;
&#xD;
      The other treatment of Dd contracture in this study is needle fasiotomy/aponeurotomy. We use&#xD;
      multiple perforation technigue with 26 G needle needle, with as little local anesthesia&#xD;
      (xylocin w adrenaline) as needed during contionus extension of the finger untill successfully&#xD;
      extended.&#xD;
&#xD;
      The two procedures leave little scar tissue lessening the challenges posed by the&#xD;
      reoperations.&#xD;
&#xD;
      Recurrence rate of contracture following different treatments of Dupuytren's disease differs&#xD;
      widely in the literature, and the rate is influenced by multiple factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Total Passive Extension Deficit</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Dash (Disabilities of the shoulder and Hand)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D (Euroqol 5 Dimensions)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief MHQ (Michigan Hand Questionare)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>URAM (Unité Rhumatologique des Affections de la Main)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Jamar grip strength</measure>
    <time_frame>1,4,26 weeks and one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual analogue scale) pain</measure>
    <time_frame>1,4,26 weeks and one year</time_frame>
    <description>0 is no pain, 10 maximum pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual analogue sale) satisfaction</measure>
    <time_frame>1,4,26 weeks. 1,2 and 5 years</time_frame>
    <description>0 is not satisfied, 10 maximum satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1,4,weeks One year</time_frame>
    <description>AE,SAE,SUSAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>1,4,26 weeks. 1,2 and 5 years</time_frame>
    <description>def. 30 degrees of treated MCP joint, or 20 or more degrees of adjecent PIPJ</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Dupuytren Contracture</condition>
  <arm_group>
    <arm_group_label>Needle aponeurotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>percutaneous transection or pretendinous palmar dupytren cord</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiapex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiapex</intervention_name>
    <description>Injection of collagenase of primary dupytren cord</description>
    <arm_group_label>Xiapex</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Needle aponeurotomy</intervention_name>
    <description>26 G needle multiple perforation tecqnique with local anesthetic</description>
    <arm_group_label>Needle aponeurotomy</arm_group_label>
    <other_name>Percutaneous needle fasiotomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary Dd disease (no earlier treatment for this condition of the hand involved)&#xD;
&#xD;
          -  Single digit involvement, one of the three ulnar digits&#xD;
&#xD;
          -  Average norwegian language skills.&#xD;
&#xD;
          -  MCPJ contracture of 30 degrees or more and less than 20 degree involvement of the&#xD;
             adjacent PIPJ&#xD;
&#xD;
          -  Minimum 18 y.o.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement of 2 fingers/joints&#xD;
&#xD;
          -  Earlier treatment for Dd disease of the same hand, affection of addjecent PIPJ of 20&#xD;
             degrees or mor&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Ongoing treatment with platelet inhibitors&#xD;
&#xD;
          -  Treatment with tetracycline 2 weeks prior to treatment date&#xD;
&#xD;
          -  Poor norwegian language skills&#xD;
&#xD;
          -  Participation in other studies 4 weeks prior or after treatment date&#xD;
&#xD;
          -  &quot;Need to treat&quot; of both hands&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per-Henrik Randsborg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Ingi Thor Hauksson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Primary Dd disase</keyword>
  <keyword>MCP joint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

